Akagera Medicines, Inc
Douglas Moore is a seasoned professional in quality control and quality assurance within the pharmaceutical and biotechnology sectors. Currently serving as the Senior Director of Quality and CMC Operations at Akagera Medicines, Inc. since October 2021, Douglas previously held senior leadership roles at L.E.A.F Pharmaceuticals and Merrimack, where responsibilities included leading quality unit operations and overseeing complex analytical method transfers. With extensive experience dating back to roles at Lonza, Amgen, Genzyme, and Organogenesis, Douglas has consistently demonstrated expertise in managing quality operations, developing and implementing quality systems, and ensuring compliance with regulatory standards. Douglas holds a Master of Science in Biotechnology from the University of Rhode Island and a Bachelor of Science in Biology from Rhode Island College.
This person is not in any teams
Akagera Medicines, Inc
Akagera Medicines is developing novel liposomal formulations of antibacterial drugs to treat tuberculosis. The company was founded in 2018 in Kigali, Rwanda. It is well-funded, majority-owned by the people of Rwanda, incorporated as a Delaware corporation, and has laboratories in Boston and San Francisco. Board members and advisors include Ambassador Dr. Albrecht Conze, Dr. Paul Farmer, Dr. Donald Kaberuka, and Dr. Anne Lenaerts. Akagera Medicines intends (if toxicology and Proof of Concept efficacy studies go as anticipated) to begin IND-enabling studies in Q4 2020. The moral purpose of Akagera Medicines is to create medicines that lead to a world free of tuberculosis (TB), humankind’s greatest killer. This means improving efficacy, shortening the duration of treatment, optimizing drug/drug interaction, eliminating toxicity, and lowering the costs to patients and to society. Our Goals • to initiate clinical trials in humans in 2022; • to reduce the global incidence of TB deaths by 80% in the next decade; • to eradicate the multi-drug resistant (MDR) form of TB; • to explore the high probability that Akagera Medicines' approach will work to create treatments and vaccines in other infectious diseases like MRSA, Malaria, and HIV; • and to ensure that those treatments could be created, tested, and manufactured in the heart of Africa.